Alpha-Synuclein Mediated Hyperphosphorylation of Tau in the Genesis of
Section: For Industry
Category(ies): CNS Disorders
Reference #: SIAN422002
OTC Contact: David Humphrey (Directory Information | Send a Message)
Description
Georgetown University researchers have shown that alpha-synuclein hyperphosphorylates Tau, through the direct activation of at least two kinases, GSK-3beta and ERK. Hyperphosphorylated Tau has not previously been linked to the genesis of Parkinson’s disease and synucleopathies. Blockade of the hyperphosphorylation of Tau, will be a viable treatment strategy to prevent ongoing neurodegeneration of different brain regions.
Applications
Early stage diagnostic as well as potential treatment of Parkinson’s disease.
Advantages
Stage of Development
Stage of Development: Animal studies testing the hypothesis that reducing alpha-synuclein levels or blockade of kinases that hyperphosphorylate Tau, will prevent the degeneration of the nigrostriatal system in toxin models, and will cause arrest or reversal of degenerated neurons are underway.
Inventor: Dr. Anita Sidhu
Relevant Publications
Relevant Publications: Duka et al. Alpha-Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism. FASEB Journal 20: 2302-2312 2006.
Patent Status
U.S. and Foreign Rights protected.
